Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated for the management of type 2 diabetes mellitus, heart failure, and chronic kidney disease. It lowers blood glucose levels by promoting urinary glucose excretion through inhibition of renal glucose reabsorption in the proximal tubules.
Reviews
There are no reviews yet.